Product Code: ETC6185554 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Australias monoclonal antibody (mAb) market is witnessing robust growth due to increasing investments in biotechnology, the rise of chronic diseases, and the expansion of targeted therapies. Monoclonal antibodies are widely used in oncology, immunology, and infectious disease treatment. Government support for biologics research and collaborations between academic institutions and pharmaceutical companies have strengthened the development pipeline. Market growth is further propelled by Australia`s regulatory efficiency and favorable clinical trial environment.
The monoclonal antibody market in Australia continues to grow due to its efficacy in treating cancers, autoimmune disorders, and infectious diseases. Government incentives for biologics research and support for local biotech startups play a key role. The expansion of clinical trials and interest in biosimilars add to the momentum. However, pricing and accessibility remain debated topics, especially within public health systems.
Despite their rising demand, the monoclonal antibody market in Australia is hindered by high R&D costs and complex manufacturing processes. There is also a dependence on international suppliers for raw materials and biotechnological expertise. Additionally, patent expirations and competition from biosimilars are pressuring pricing structures, posing a significant challenge to profit margins for original biologic producers.
Australias robust biotech sector provides fertile ground for investments in monoclonal antibody development, especially in cancer, autoimmune, and infectious disease therapeutics. Venture capital and private equity can support early-stage biopharma companies or scale up biologics manufacturing capabilities. Investors can also explore partnerships with hospitals and research centers for clinical trial advancements and biosimilar introductions.
Government policies governing the monoclonal antibody market are shaped by the TGAs role in regulating therapeutic products. The TGA ensures that monoclonal antibodies, which are used for treating various diseases, meet rigorous safety and efficacy standards. Policies also incentivize research and development in biologic treatments through tax breaks and public funding. However, due to their high cost, monoclonal antibody therapies are often subject to the Pharmaceutical Benefits Scheme (PBS), which regulates reimbursements and access for patients. The government also supports the growth of the biotech sector through grants and initiatives aimed at increasing Australias manufacturing capabilities in the biologics space.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Monoclonal Antibody Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Monoclonal Antibody Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Monoclonal Antibody Market - Industry Life Cycle |
3.4 Australia Monoclonal Antibody Market - Porter's Five Forces |
3.5 Australia Monoclonal Antibody Market Revenues & Volume Share, By Source, 2021 & 2031F |
3.6 Australia Monoclonal Antibody Market Revenues & Volume Share, By Production, 2021 & 2031F |
3.7 Australia Monoclonal Antibody Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.8 Australia Monoclonal Antibody Market Revenues & Volume Share, By End use, 2021 & 2031F |
4 Australia Monoclonal Antibody Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of chronic diseases in Australia, leading to higher demand for targeted therapies like monoclonal antibodies. |
4.2.2 Growing investments in research and development activities for the development of innovative monoclonal antibody treatments. |
4.2.3 Favorable government regulations and policies supporting the adoption and usage of monoclonal antibodies in healthcare. |
4.3 Market Restraints |
4.3.1 High costs associated with monoclonal antibody therapy limiting access to treatment for some patients. |
4.3.2 Stringent regulatory processes for approval and commercialization of monoclonal antibodies, leading to delays in market entry. |
5 Australia Monoclonal Antibody Market Trends |
6 Australia Monoclonal Antibody Market, By Types |
6.1 Australia Monoclonal Antibody Market, By Source |
6.1.1 Overview and Analysis |
6.1.2 Australia Monoclonal Antibody Market Revenues & Volume, By Source, 2021- 2031F |
6.1.3 Australia Monoclonal Antibody Market Revenues & Volume, By Murine, 2021- 2031F |
6.1.4 Australia Monoclonal Antibody Market Revenues & Volume, By Chimeric, 2021- 2031F |
6.1.5 Australia Monoclonal Antibody Market Revenues & Volume, By Humanized, 2021- 2031F |
6.1.6 Australia Monoclonal Antibody Market Revenues & Volume, By Human, 2021- 2031F |
6.2 Australia Monoclonal Antibody Market, By Production |
6.2.1 Overview and Analysis |
6.2.2 Australia Monoclonal Antibody Market Revenues & Volume, By In Vivo, 2021- 2031F |
6.2.3 Australia Monoclonal Antibody Market Revenues & Volume, By In Vitro, 2021- 2031F |
6.3 Australia Monoclonal Antibody Market, By Indication |
6.3.1 Overview and Analysis |
6.3.2 Australia Monoclonal Antibody Market Revenues & Volume, By Cancer, 2021- 2031F |
6.3.3 Australia Monoclonal Antibody Market Revenues & Volume, By Autoimmune Diseases, 2021- 2031F |
6.3.4 Australia Monoclonal Antibody Market Revenues & Volume, By Inflammatory Diseases, 2021- 2031F |
6.3.5 Australia Monoclonal Antibody Market Revenues & Volume, By Infectious Diseases, 2021- 2031F |
6.3.6 Australia Monoclonal Antibody Market Revenues & Volume, By Microbial Diseases, 2021- 2031F |
6.3.7 Australia Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Monoclonal Antibody Market, By End use |
6.4.1 Overview and Analysis |
6.4.2 Australia Monoclonal Antibody Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 Australia Monoclonal Antibody Market Revenues & Volume, By Research Institutes, 2021- 2031F |
6.4.4 Australia Monoclonal Antibody Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Monoclonal Antibody Market Import-Export Trade Statistics |
7.1 Australia Monoclonal Antibody Market Export to Major Countries |
7.2 Australia Monoclonal Antibody Market Imports from Major Countries |
8 Australia Monoclonal Antibody Market Key Performance Indicators |
8.1 Number of clinical trials for monoclonal antibody therapies conducted in Australia. |
8.2 Adoption rate of monoclonal antibodies in different therapeutic areas. |
8.3 Number of partnerships and collaborations between pharmaceutical companies and research institutions for monoclonal antibody development. |
8.4 Patient outcomes and improvements in quality of life metrics with the use of monoclonal antibody treatments. |
8.5 Investment trends in the monoclonal antibody market in Australia. |
9 Australia Monoclonal Antibody Market - Opportunity Assessment |
9.1 Australia Monoclonal Antibody Market Opportunity Assessment, By Source, 2021 & 2031F |
9.2 Australia Monoclonal Antibody Market Opportunity Assessment, By Production, 2021 & 2031F |
9.3 Australia Monoclonal Antibody Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.4 Australia Monoclonal Antibody Market Opportunity Assessment, By End use, 2021 & 2031F |
10 Australia Monoclonal Antibody Market - Competitive Landscape |
10.1 Australia Monoclonal Antibody Market Revenue Share, By Companies, 2024 |
10.2 Australia Monoclonal Antibody Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |